Comparing Chemotherapy Treatments for Bladder Cancer
Author Information
Author(s): GM Mead, M Russell, P Clark, SJ Harland, PG Harper, R Cowan, JT Roberts, BM Uscinska, GO Griffiths, MKB Parmar
Primary Institution: Medical Research Council
Hypothesis
Does adding cisplatin to methotrexate and vinblastine improve survival in patients with advanced transitional cell carcinoma?
Conclusion
The addition of cisplatin to methotrexate and vinblastine improves survival and progression-free survival in patients with advanced transitional cell carcinoma, despite increased toxicity.
Supporting Evidence
- The hazard ratio for overall survival was 0.68 in favor of CMV.
- CMV treatment resulted in a 13% absolute improvement in 1-year survival.
- Patients receiving CMV had a median survival of 7 months compared to 4.5 months for MV.
- CMV was associated with higher toxicity, including treatment-related deaths.
Takeaway
This study shows that a specific combination of cancer drugs can help people live longer, but it can also make them feel worse.
Methodology
A multicentre randomized trial comparing two chemotherapy regimens in patients with advanced transitional cell carcinoma.
Potential Biases
Potential bias due to the inclusion of patients with mixed tumor types and varying health statuses.
Limitations
The study included patients with varying degrees of health and previous treatments, which may affect the generalizability of the results.
Participant Demographics
Patients were primarily elderly, with a median age of 65, and included both males and females.
Statistical Information
P-Value
0.0065
Confidence Interval
0.51-0.90
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website